BrainsWay (NASDAQ:BWAY) Shares Up 3.2%

BrainsWay Ltd. (NASDAQ:BWAY)’s stock price traded up 3.2% on Monday . The stock traded as high as $7.67 and last traded at $7.38. 71,493 shares traded hands during trading, a decline of 25% from the average session volume of 95,061 shares. The stock had previously closed at $7.15.

Analysts Set New Price Targets

BWAY has been the topic of several analyst reports. Northland Securities lifted their target price on shares of BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. HC Wainwright raised their price objective on BrainsWay from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th.

BrainsWay Stock Up 3.2 %

The stock’s fifty day moving average is $7.11 and its two-hundred day moving average is $6.24. The firm has a market capitalization of $123.10 million, a price-to-earnings ratio of -81.99 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last released its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $10.01 million during the quarter, compared to analysts’ expectations of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same period in the prior year, the company earned ($0.05) earnings per share. As a group, analysts anticipate that BrainsWay Ltd. will post 0.06 EPS for the current year.

Hedge Funds Weigh In On BrainsWay

Several institutional investors and hedge funds have recently bought and sold shares of the company. Tucker Asset Management LLC grew its position in shares of BrainsWay by 1,686.9% in the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after buying an additional 5,145 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of BrainsWay during the 1st quarter valued at $60,000. Quadrature Capital Ltd bought a new position in shares of BrainsWay in the fourth quarter worth approximately $70,000. Rhumbline Advisers lifted its holdings in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after purchasing an additional 1,695 shares in the last quarter. Finally, Perritt Capital Management Inc bought a new stake in shares of BrainsWay in the second quarter worth about $121,000. 30.11% of the stock is owned by institutional investors.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.